Swiss drugmaker Novartis on Monday received European Commission approval for Kymriah, its CAR-T cell therapy, to treat children with a form of leukemia and adults with lymphoma.
from Latest News https://ift.tt/2MUiFxN
Novartis's Kymriah wins EU approval for blood cancer treatment
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment